Lifestyle genomics and the metabolic syndrome: A review of genetic variants that influence response to diet and exercise interventions

2018 ◽  
Vol 59 (13) ◽  
pp. 2028-2039 ◽  
Author(s):  
Peri H. Fenwick ◽  
Khursheed Jeejeebhoy ◽  
Rupinder Dhaliwal ◽  
Dawna Royall ◽  
Paula Brauer ◽  
...  
2011 ◽  
Vol 12 (11) ◽  
pp. 952-967 ◽  
Author(s):  
C. M. Povel ◽  
J. M. A. Boer ◽  
E. Reiling ◽  
E. J. M. Feskens

2009 ◽  
Vol 158 (2) ◽  
pp. 257-262.e1 ◽  
Author(s):  
Alessandra C. Goulart ◽  
Kathryn M. Rexrode ◽  
Suzanne Cheng ◽  
Lynda Rose ◽  
Julie E. Buring ◽  
...  

2007 ◽  
Vol 21 (6) ◽  
Author(s):  
J Jitomir ◽  
R Chandran ◽  
B Shelmadine ◽  
K Beavers ◽  
C Kerksick ◽  
...  

2005 ◽  
Vol 64 (3) ◽  
pp. 349-357 ◽  
Author(s):  
D. I. Shaw ◽  
W. L. Hall ◽  
C. M. Williams

Obesity and overweight are linked with a cluster of metabolic and vascular disorders that have been termed the metabolic syndrome. Although there is not yet a universally-accepted set of diagnostic criteria, most expert groups agree that the syndrome is characterised by impaired insulin sensitivity and hyperglycaemia, dyslipidaemia (elevated blood triacyglycerols with depressed HDL-cholesterol), abdominal obesity and hypertension. Based on existing published criteria estimates suggest that the syndrome affects a substantial percentage of the middle-aged and elderly populations of most European countries (10–20%) and confers increased risk of type 2 diabetes (2–8.8-fold) and CVD (1.5–6-fold), as well as having a marked effect on morbidity. Although the pathophysiology is incompletely understood, insulin resistance and abdominal obesity are central to subsequent abnormalities in circulating glucose and lipoproteins, and vascular function that lead to type 2 diabetes, atherosclerosis and CVD. The link between metabolic syndrome, type 2 diabetes and CVD, as well as inability to reverse the present rising rates of obesity, will lead to economically-unsustainable costs of health care in the next 10–20 years. Preventative strategies for metabolic syndrome are required to slow rates of progression and to reduce dependence on costly medical management. A notable development is recent evidence that shows that diet and exercise are more effective than drug treatment in preventing the development of type-2 diabetes in high-risk individuals. The LIPGENE project will investigate dietary fat quality as a strategy for the prevention of metabolic syndrome and identify food chain approaches that can support consumer attempts to alter their dietary patterns.


Diabetes ◽  
2007 ◽  
Vol 57 (1) ◽  
pp. 209-217 ◽  
Author(s):  
S. Wiedmann ◽  
M. Fischer ◽  
M. Koehler ◽  
K. Neureuther ◽  
G. Riegger ◽  
...  

2013 ◽  
Vol 72 (3) ◽  
pp. 310-316 ◽  
Author(s):  
Catherine M. Champagne ◽  
George A. Bray

Diagnosis of metabolic syndrome includes a set of laboratory and physical findings, including central adiposity, elevated TAG, reduced HDL-cholesterol, hypertension and elevated fasting glucose or insulin resistance. While definitions have varied slightly, from a practical point of view, identifying dietary and lifestyle factors, including low levels of physical activity, are important in designing a diet and exercise programme that can help individuals with the metabolic syndrome to reduce the associated detrimental health consequences. Specific features of the metabolic syndrome require intervention, whether dietary or otherwise, to move towards normal ranges. It is important to remember that no one size or treatment fits all. While central obesity is perceived as the hallmark of the metabolic syndrome, other features need to be treated independently if they do not respond to lifestyle change. The future may hold treatments for the metabolic syndrome that involve modulation of inflammation.


Sign in / Sign up

Export Citation Format

Share Document